The global oral proteins and peptides market size reached US$ 1.7 Billion in 2023. Looking forward, the market is projected to reach US$ 3.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.65% during 2023-2032. The expanding prevalence of chronic diseases, the rising geriatric population, and the increasing preference for oral drugs among consumers represent some of the key factors driving the market.
Proteins and peptides are natural components of the human body and play essential roles in many biological processes. Due to their complex structure and susceptibility to digestion in the stomach and small intestine, they are usually administered through injections. However, oral proteins and peptides can be taken via the oral path to treat hormonal, gastric, and metabolic disorders.
They are designed to overcome these challenges by using specialized formulations that protect the molecules from digestion and allow them to be absorbed through the intestinal wall into the bloodstream. These formulations include enteric coatings, nanoparticles, and other delivery technologies. Oral proteins and peptides are extensively utilized to treat numerous chronic diseases, such as diabetes, cancer, and autoimmune disorders.
In addition to this, innovative technological advancements, such as three-dimensional (3D) printing, nanotechnology, and genetic engineering, have enabled manufacturers to produce more advanced and cost-effective product variants, which is acting as another significant growth-inducing factor. Concurrent with this, the extensive collaborative efforts between pharmaceutical companies, significant advancements in the healthcare infrastructure, and rising research and development (R&D) activities are presenting remunerative growth opportunities for the market. Furthermore, the inflating disposable income of consumers, the widespread adoption of protein-rich diets, the surging demand for protein powder, bars, and shakes, and the increasing proliferation of online platforms providing easy product access are aiding in market expansion.
Proteins and peptides are natural components of the human body and play essential roles in many biological processes. Due to their complex structure and susceptibility to digestion in the stomach and small intestine, they are usually administered through injections. However, oral proteins and peptides can be taken via the oral path to treat hormonal, gastric, and metabolic disorders.
They are designed to overcome these challenges by using specialized formulations that protect the molecules from digestion and allow them to be absorbed through the intestinal wall into the bloodstream. These formulations include enteric coatings, nanoparticles, and other delivery technologies. Oral proteins and peptides are extensively utilized to treat numerous chronic diseases, such as diabetes, cancer, and autoimmune disorders.
Oral Proteins and Peptides Market Trends
The increasing volume of patients suffering from chronic diseases, such as cancer, diabetes, cardiovascular disorders (CVDs), and acquired immunodeficiency syndrome (AIDs), and the expanding geriatric population represent the key factors driving the oral proteins and peptides market growth. Besides this, shifting preferences and the rising demand for effective oral drugs and technology among the masses are contributing to the market growth. Moreover, the escalating consumer health consciousness and the growing awareness of the numerous benefits associated with the consumption of oral protein and peptide supplements are creating a positive outlook for the market.In addition to this, innovative technological advancements, such as three-dimensional (3D) printing, nanotechnology, and genetic engineering, have enabled manufacturers to produce more advanced and cost-effective product variants, which is acting as another significant growth-inducing factor. Concurrent with this, the extensive collaborative efforts between pharmaceutical companies, significant advancements in the healthcare infrastructure, and rising research and development (R&D) activities are presenting remunerative growth opportunities for the market. Furthermore, the inflating disposable income of consumers, the widespread adoption of protein-rich diets, the surging demand for protein powder, bars, and shakes, and the increasing proliferation of online platforms providing easy product access are aiding in market expansion.
Key Market Segmentation
This report provides an analysis of the key trends in each segment of the global oral proteins and peptides market, along with forecasts at the global, regional, and country levels from 2024-2032. The report has categorized the market based on drug type and application.Drug Type Insights:
- Linaclotide
- Plecanatide
- Calcitonin
- Insulin
- Octreotide
Application Insights:
- Gastric and Digestive Disorders
- Bone Diseases
- Diabetes
- Hormonal Disorders
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global oral proteins and peptides market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amryt Pharma Plc, AstraZeneca PLC, Biocon Limited, Novo Nordisk A/S, Oramed Ltd, Proxima Concepts Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report
- How has the global oral proteins and peptides market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global oral proteins and peptides market?
- What is the impact of each driver, restraint, and opportunity on the global oral proteins and peptides market?
- What are the key regional markets?
- Which countries represent the most attractive oral proteins and peptides market?
- What is the breakup of the market based on the drug type?
- Which is the most attractive drug type in the oral proteins and peptides market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the oral proteins and peptides market?
- What is the competitive structure of the global oral proteins and peptides market?
- Who are the key players/companies in the global oral proteins and peptides market?
Table of Contents
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Oral Proteins and Peptides Market
6 Market Breakup by Drug Type
7 Market Breakup by Application
8 Market Breakup by Region
9 Drivers, Restraints, and Opportunities
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Amryt Pharma Plc
- AstraZeneca PLC
- Biocon Limited
- Novo Nordisk A/S
- Oramed Ltd
- Proxima Concepts Limited
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 136 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 1.7 Billion |
| Forecasted Market Value ( USD | $ 3.3 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 6 |
